SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
CNS TREATMENT STRATEGIES: RISK AND BENEFITS
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
THEMED DISCUSSION LEADER
Ned Sacktor
Johns Hopkins University, Baltimore, MD, USA
CAN WE AFFORD TO WAIT? ART AND THE CNS
Kevin Robertson
University of North Carolina - Chapel Hill, Chapel Hill, NC, USA
COGNITIVE TRAJECTORIES OVER 4 YEARS AMONG HIV+ WOMEN WITH OPTIMAL VIRAL SUPPRESSION
Leah H Rubin
University of Illinois at Chicago, Chicago, IL, USA
CENICRIVIROC IMPROVES NEUROCOGNITION AND REDUCES MONOCYTE ACTIVATION IN TREATED HIV
Michelle L D'Antoni
University of Hawaii, Honolulu, HI, USA
CSF INFLAMMATORY MARKERS AFTER ADDING MARAVIROC TO MONOTHERAPY DARUNAVIR/RITONAVIR
Tristan Barber
Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
EXTENSIVE EFAVIRENZ METABOLISM IS ASSOCIATED WITH GREATER CNS TOXICITY
Robert Gross
University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
